Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 17.15 USD -0.17% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Travere Therapeutics Inc?
Write Note

Travere Therapeutics Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Travere Therapeutics Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Travere Therapeutics Inc
NASDAQ:TVTX
Total Current Liabilities
$190m
CAGR 3-Years
19%
CAGR 5-Years
17%
CAGR 10-Years
14%
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%
No Stocks Found

Travere Therapeutics Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Travere Therapeutics Inc., a biopharmaceutical trailblazer, has carved a niche in the healthcare landscape by focusing on the often-overlooked realm of rare diseases. With a mission to improve the lives of patients grappling with conditions that lack sufficient treatment options, Travere leverages its deep expertise in research, development, and commercialization of therapies. Beyond generic pharmaceuticals, the company's extensive pipeline is filled with innovative treatments, targeting conditions from chronic kidney diseases to rare liver disorders. This strategic emphasis on rare diseases not only exemplifies Travere's commitment to social responsibility but also positions it uniquely within the competitive pharmaceutical sector, where the rarity of these conditions often results in limited competition. The financial lifeline of Travere Therapeutics comes from its ability to navigate the intricate process of bringing drugs from conception to market. Revenue streams are primarily driven by the sales of FDA-approved products, alongside milestone and royalty payments tied to strategic collaborations. The company’s shrewd strategy involves acquiring or licensing promising compounds and utilizing its robust in-house capabilities to carry these assets through clinical trials. This intertwined web of internal development and strategic partnerships creates a sustainable business model. It ensures that as current treatments mature and stabilize their market presence, new pipeline products are continually groomed, keeping revenue streams dynamic while reinforcing their commitment to addressing unmet medical needs.

TVTX Intrinsic Value
29.25 USD
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Travere Therapeutics Inc's Total Current Liabilities?
Total Current Liabilities
190m USD

Based on the financial report for Sep 30, 2024, Travere Therapeutics Inc's Total Current Liabilities amounts to 190m USD.

What is Travere Therapeutics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
14%

Over the last year, the Total Current Liabilities growth was 36%. The average annual Total Current Liabilities growth rates for Travere Therapeutics Inc have been 19% over the past three years , 17% over the past five years , and 14% over the past ten years .

Back to Top